Back to Search
Start Over
Targeted In VivoGeneration of CAR T and NK Cells Utilizing an Engineered Lentiviral Vector Platform
- Source :
- Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p763-763, 1p
- Publication Year :
- 2023
-
Abstract
- CAR T cell therapies have revolutionized the treatment of B cell malignancies. Ex vivoCAR manufacturing is complex, costly, and cumbersome, prompting efforts that develop shorter manufacturing and allogeneic or “universal donor” strategies. Conventional ex vivoCAR T cell therapy is not widely accessible and financial burdens to patients further hinder access to care. Furthermore, recent data show that CAR T product efficacy is correlated with reduced ex vivomanipulation of cells.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 142
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs64589228
- Full Text :
- https://doi.org/10.1182/blood-2023-189087